Stocks Health care NEUP
NASDAQ · Health careNeuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. reported revenue of $1.2M in fiscal 2026, down 92.5% from a year earlier. It posted a net loss of $13.5M. At June 30, 2026 it held $19.9M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on September 18, 2026.
What Neuphoria Therapeutics Inc. does
Neuphoria Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NEUP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $1.2M | -$13.5M | -$3.06 | n/a |
| 2025 | $15.6M | -$369.6K | -$0.23 | n/a |
| 2024 | n/a | -$15.5M | -$18.62 | n/a |
| 2024 | n/a | -$21.4M | -$37.24 | n/a |
Where NEUP ranks in Health care
Latest SEC filings
What Neuphoria Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026Additional proxy material DEFA14A
- September 18, 2026Additional proxy material DEFA14A
- September 18, 2026Proxy statement DEF 14A
- September 18, 2026Annual report 10-K · period to June 30, 2026Revenue fell 92% to $1.2M versus the prior year; diluted EPS -$3.06 versus -$0.23.
- July 28, 2026Passive stake changed SCHEDULE 13G/A
- July 24, 2026Additional proxy material DEFA14A
- July 24, 2026
- May 26, 2026Other event 8-K
- May 15, 2026
- February 17, 2026
Who owns NEUP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lynx1 Capital Management LP13D, may seek influence with 1 related filers | 16.3% | December 29, 2025 |
| Shay Capital LLC13G, passive with 1 related filers | 7.3% | October 31, 2025 |
Largest institutional holders
Insiders
Questions about NEUP
What does Neuphoria Therapeutics Inc. do?
Neuphoria Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NEUP.
Is Neuphoria Therapeutics Inc. profitable?
No. In fiscal 2026 it reported a net loss of $13.5M on revenue of $1.2M.
How much revenue does Neuphoria Therapeutics Inc. make?
In fiscal 2026 Neuphoria Therapeutics Inc. reported revenue of $1.2M. That is 92.5% less than a year earlier.
When did Neuphoria Therapeutics Inc. last report?
Its most recent periodic report is the annual report (10-K) filed on September 18, 2026. It covers the period to June 30, 2026.
Similar companies
Compare NEUP with
Follow NEUP
Get an email when Neuphoria Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow NEUP: get an email when it filesWhere the numbers come from
Financial figures are the values Neuphoria Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.